Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne

Leon H. Kircik, Edward Lain, Michael Gold, Bruce Katz, Hilary Baldwin, Eric Guenin, Anya Loncaric, Radhakrishnan Pillai

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


BACKGROUND: In two phase 3 trials (NCT03168334, NCT03168321), participants with moderate-to-severe acne had significant symptom improvements after 12 weeks of treatment with tazarotene 0.045% lotion. Given the negative psychosocial effects of acne on patients, data from these studies were analyzed to evaluate quality of life in various subgroups. METHODS: Mean changes from baseline to week 12 in Acne-Specific Quality of Life (Acne-QoL) domain and item scores were analyzed in the pooled intent-to-treat (ITT) population and in participants who were categorized as follows: Evaluator's Global Severity Score (EGSS) score=3 (“moderate”) or score=4 (“severe”) at baseline; Acne-QoL total score ≥60 (better quality of life) or <60 (worse quality of life), based on the median score at baseline. Exploratory analyses based on sex and race were also performed. RESULTS: In the pooled ITT population (N=1614), Acne-QoL improvements were greater with tazarotene 0.045% lotion versus vehicle lotion, with significant differences in the acne symptoms domain, 3 acne symptom items, 2 self-perception items, 1 role-emotional item, and 1 role-social item (all P<0.05). Acne-QoL improvements with tazarotene 0.045% lotion were comparable between the EGSS subgroups. However, participants who self-reported worse quality of life at baseline (Acne-QoL total score <60) had notably greater improvements than those with better quality of life. Female and Black participants had greater Acne-QoL improvements than male and White participants. CONCLUSIONS: Participants treated with tazarotene 0.045% lotion had significant quality-of-life improvements. Clinician-rated symptom severity appeared to have a smaller effect on Acne-QoL outcomes than participants’ own assessments of quality of life. J Drugs Dermatol. 2020;19(11): doi:10.36849/JDD.2020.5457.

Original languageEnglish
Pages (from-to)1086-1092
Number of pages7
JournalJournal of Drugs in Dermatology
Issue number11
StatePublished - 1 Nov 2020


Dive into the research topics of 'Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne'. Together they form a unique fingerprint.

Cite this